Aspen Neuroscience Receives $6.5M for Parkinson’s Stem Cell Therapy – Parkinson’s News Today

Aspen Neuroscience, a new biotech company, has raised $6.5 million to develop cell therapies for Parkinsons disease using patients own cells.

The company was co-founded by renowned stem cell scientists Jeanne F. Loring, PhD, and Andres Bratt-Leal, PhD, and initially supported by Summit for Stem Cell, a non-profit organization that provides a variety of services for Parkinsons patients.

Parkinsons hallmark motor symptomsinclude tremor, slowness of movement (bradykinesia), stiffness (rigidity), uncontrollable movements (dyskinesia), and poor balance.

As the disease progresses, patients typically need to gradually increase their dopaminergic therapeutic dose for maximum benefit. Even after that they might sometimes experience reappearance or worsening of symptoms due to diminishing effects of dopaminergic therapy, known was off periods.

Importantly, dopaminergic therapy is delivered to areas of the brain other than the striatum, a key motor control region severely affected in Parkinsons disease. Because of the therapys off-target behavior, patients also may experience side effects such as hallucinations or cognitive impairment.

Aspen wants to combine its expertise in stem cell biology, genomics and neurology and develop the first autologous (self) stem cell-based therapy for Parkinsons disease.

In this type of cell therapy, a patients own cells (usually skin cells) are reprogrammed back into a stem cell-like state, which allows the development of an unlimited source of almost any type of human cell needed, including dopamine-producing neurons, which are those mainly affected by this disorder.

Because these cells are derived from patients, they do not carry the risk of being rejected once re-implanted, eliminating the need for immunosuppressive complementary therapies, which carry serious side effects such as infections and possibly limiting therapeutic potential.

In theory, replacing lost dopaminergic neurons with new stem cell-derived dopamine-producing ones could potentially ease or reverse motor symptoms associated with the disease.

Aspen is developing a restorative, disease modifying autologous neuron therapy for people suffering from Parkinsons disease, Howard J. Federoff, MD, PhD, Aspens CEO, said in a press release.

We are fortunate to have such a high-caliber scientific and medical leadership team to make our treatments a reality. Our cell replacement therapy, which originated in the laboratory of Dr. Jeanne Loring and was later supported by Summit for Stem Cell and its President, Ms. Jenifer Raub, has the potential to release dopamine and reconstruct neural networks where no disease-modifying therapies exist, Federoff said.

The companys lead product (ANPD001) is undergoing investigational new drug (IND)-enabling studies for the treatment of sporadic Parkinsons disease. Aspen experts also are developing a gene-editing treatment (ANPD002) for familial forms of Parkinsons, starting with the most common genetic variant in the GBAgene, which provides instructions to make the enzyme beta-glucocerebrosidase.

The new seed funding round was led by Domain Associates and Axon Ventures, with additional participation from Alexandria Venture Investments, Arch Venture Partners, OrbiMed and Section 32, according to the press release.

With over three years of experience in the medical communications business, Catarina holds a BSc. in Biomedical Sciences and a MSc. in Neurosciences. Apart from writing, she has been involved in patient-oriented translational and clinical research.

Total Posts: 208

Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.

Follow this link:
Aspen Neuroscience Receives $6.5M for Parkinson's Stem Cell Therapy - Parkinson's News Today

BioRestorative Therapies Featured in IEEE Pulse Magazine’s Cover Story About Stem Cell Therapies for Low Back Pain – GlobeNewswire

MELVILLE, N.Y., Dec. 16, 2019 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (BioRestorative or the Company) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, announced today feature coverage in the news outlet, IEEE Pulse, a magazine of the IEEE Engineering in Medicine and Biology Society. According to IEEE, it is the worlds largest technical professional organization for the advancement of technology.

To view the IEEE Pulse Magazines article featuring BioRestorative, click here.

The published cover-story article features commentary from Francisco Silva, Chief Scientist and Vice President of Research and Development for BioRestorative, regarding BRTX-100, the Companys lead therapeutic candidate for chronic lumbar disc disease. Once the U.S. Food and Drug Administration (FDA) authorizes the sale of BRTX-100, we would ship it to your doctor, and with a 30-minute procedure the material would be injected into your disc in a 1.5 ml solution, explains Silva. He elaborates on the product, discussing growing and expanding stem cells from the patients bone marrow under hypoxic conditions that mimic those in the normal intervertebral space. We are enriching the cells to be able to survive in this harsh environment, says Silva.

In addition to BRTX-100, the magazine article also highlights BioRestoratives other research pursuit, its ThermoStem program, utilizing brown adipose (fat) derived stem cells to target treatment of metabolic diseases and disorders, like diabetes, obesity and hypertension.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

Disc/Spine Program (brtxDISC): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a persons own) cultured mesenchymal stem cells collected from the patients bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders. The BRTX-100 production process utilizes proprietary technology and involves collecting a patients bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patients damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat persistent lower back pain due to painful degenerative discs.

Metabolic Program (ThermoStem): We are developing a cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, whether the Company will be able to consummate the private placement and the satisfaction of closing conditions related to the private placement and those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:Email: ir@biorestorative.com

The rest is here:
BioRestorative Therapies Featured in IEEE Pulse Magazine's Cover Story About Stem Cell Therapies for Low Back Pain - GlobeNewswire

UCSF’s 11 Most Popular Health and Science Stories of 2019 – UCSF News Services

New technologies that could soon diagnose Alzheimers and restore speech to the paralyzed; potential new avenues in treating diabetes, multiple sclerosis and Down syndrome; and a genetic test that dramatically saved a babys life these were among the science and health topics that most engaged our readers in 2019.

Look back at these 11 stories of the past year or discover them for the first time they reflect the exciting, transformative research that takes place at UC San Francisco every day of the year.

Researchers trained a machine-learning algorithm on nearly 2,000 brain scans and then challenged it to detect early-stage Alzheimers disease in other scans. The algorithm performed with flying colors, catching the disease six years before a clinical diagnosis a lead time that may eventually help doctors treat the disease.

Continue reading

For California, a 1 percent drop in the smoking rate could mean $630 million of Medicaid savings the following year. Thats because quitting smoking can reduce many health risks relatively quickly, including heart attacks, lung disease and pregnancy complications, as well as cut long-term health risks such as cancer.

Continue reading

For the first time, researchers were able to transform human stem cells into mature insulin-producing cells similar to the pancreatic beta cells destroyed by type 1 diabetes. The breakthrough came after the team applied a key tenet of biology, that form follows function, to the way they were growing the cells in the lab.

Continue reading

Researchers took a new approach to studying Down syndrome focusing on the conditions effect on the protein-making machinery inside cells. In a mouse model of Down syndrome, they found that cells in the brain were tamping down on protein production, leading to cognitive deficits. They were able to activate protein production and improve memory and learning with a drug called ISRIB.

Continue reading

A sophisticated brain-machine interface could one day give voice to people who have lost the ability to speak due to paralysis or other neurological damage. Researchers first mapped participants brain activity to their vocal tract movements as they made various sounds. An algorithm could then translate new brain activity into movements of the virtual vocal tract and produce realistic speech.

Continue reading

Whats the best way to eat your vegetables? Should you take supplements? Low-fat, low-carb, intermittent fasting do any diets actually work? Experts weigh in on the latest science behind healthy eating and separate food fact from food fiction. Keep these evidence-based tips in mind for the holidays and in the years to come.

Continue reading

Baby Quincy was deteriorating fast from an aggressive blood cancer and too sick to undergo a stem cell transplant, his only chance at a cure. Determined to leave no stone unturned, Quincys doctors ordered the UCSF500 a new comprehensive cancer gene panel test that helped to reveal an unusual genetic alteration in his cancer and identified a long-shot therapy.

Continue reading

Multiple sclerosis (MS) is an autoimmune disease caused by immune cells that attack the protective coating around nerve cells. In a surprise, researchers discovered that other immune cells in the gut, known as plasma cells, can reduce the brain inflammation that results from the disease. Expanding these gut plasma cells may be a new therapeutic approach to treating MS.

Continue reading

Cooking food changes not only how it tastes but how our gut microbial ecosystems respond. In mice, researchers found that cooked vegetables altered their gut microbiome and caused them to lose weight. In human participants, three days of raw or cooked diets prepared by a professional chef also changed gut microbiomes, but in different ways perhaps holding clues to how our microbes have adapted to human culinary culture.

Continue reading

Alcohol-associated liver disease has become the top reason for U.S. liver transplants, making up more than one-third of liver transplants in 2016. The increase is largely due to a shift away from a common rule that required patients to abstain from alcohol and drug use for at least six months prior to transplant. A 2011 study found that transplants could be successful without this minimum sobriety period, changing the policy at many centers.

Continue reading

The emotional tumult of teenage years may in part be due to transformations in the brain. Most human brain cells mature in the first years of life, but a group of neurons in the amygdala, which controls emotional responses, dont mature until adolescence and a small number remain immature throughout life. The brain may hold on to these Peter Pan neurons to keep the brains emotional responses flexible and adaptable into old age.

Continue reading

In 2019, UCSF drove advancements in care delivery, scientific discovery, education, public service, and more. See the highlights

Follow this link:
UCSF's 11 Most Popular Health and Science Stories of 2019 - UCSF News Services

New research targets stem cells that drive aggressive blood cancer – Griffith News

Griffith University researchers played a key role in identifying that particular enzymes are critical for regulating leukemic stem cells.

In collaborative research published in Nature, the team found a way to target acute myeloid leukaemia (AML) at its source a discovery that could yield a more effective treatment for this aggressive and often incurable blood cancer.

Led by the Peter MacCallum Cancer Centre in Melbourne, Professor Vicky Averys team from the Griffith Research Institute for Drug Discovery contributed to the publication by developing essential cellular assays.

These wereutilisedtoidentify and evaluatehighly selective small molecule inhibitors that discriminatedbetween the major families of histone acetyltransferases(HAT),whichplay pivotal rolesin leukaemiastem cellregulation.

Thisresearch providesvalidation ofHBO1as a target forcancerdrug discovery, Professor Avery said.

Ithas the potential to significantly impact future therapeutic interventions for cancers in urgent need of novel therapeutic strategies.

Prof Mark Dawson and Dr Laura MacPherson led the international research team, in collaboration with researchers in Europe and Australia including at the Walter and Eliza Hall Institute of Medical Research (WEHI), Monash Institute for Pharmaceutical Sciences (MIPS) and Cancer Therapeutics CRC.

They identified a new druggable target in AML stem cells, which are the roots that sustain this type of cancer. Although these stem cells are rare, they are likely to be the main cause for resistance to current anti-cancer therapies.

Our current treatments for AML are good at eliminating the majority of cancer cells but they can leave these rare leukemic stem cells behind, resulting in the cancer coming back after treatment, Prof Dawson said.

There is a critical need for new AML treatments that eradicate these stem cells, and with this discovery weve taken a major step towards such a treatment.

In the paper the scientists described how the protein HBO1 was essential for the survival of leukemic stem cells. When HBO1 is lost, these cells are no longer ableto drive cancer growth in laboratory models of human and mouse AML.

We found that HBO1 loss caused these difficult-to-treat leukemic stem cells to cease dividing, transition to less malignant forms and, in some cases, undergo cell death, study lead author Dr MacPherson said.

The scientists then undertook a series of experiments to discover the part of the HBO1 protein that was critical for its function in stem cells. In collaboration with medicinal chemists in Melbourne, the team developed a small molecule the first building block of a drug that could suppress the activity of HBO1 in AML cells.

When we treated a range of human and mouse AML cells with a drug that inhibits HBO1 in the laboratory, we discovered that this compound potently induced anti-cancer effects, Dr MacPherson said.

Read more:
New research targets stem cells that drive aggressive blood cancer - Griffith News

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market is Projected to Reach US$XX by the end of 2018 – 2026 – Markets Gazette 24

In-depth Study of the Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market

Transparency Market Research recently published a market study that provides an in-depth understanding of the various factors that are anticipated to shape the growth of the Platelet Rich Plasma and Stem Cell Alopecia Treatment market such as the challenges, trends, drivers, and opportunities. The report further throws light on the structure of the Platelet Rich Plasma and Stem Cell Alopecia Treatment market across various regions along with an analysis of the business environment of each region.

The key indicators of market growth such as supply chain analysis, value chain analysis, and compounded annual growth rate are thoroughly discussed in the report. The presented data aims to enable readers to understand the quantitative and qualitative growth aspects of the Platelet Rich Plasma and Stem Cell Alopecia Treatment market in detail.

Request Sample Report @ https://www.transparencymarketresearch.co/sample/sample.php?flag=B&rep_id=55800

Unbiased Insights Presented in the Report:

The report clarifies the following uncertainties related to the Platelet Rich Plasma and Stem Cell Alopecia Treatment market:

Request For Discount On This Report @ https://www.transparencymarketresearch.co/sample/sample.php?flag=D&rep_id=55800

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Segmentation Analysis

The Platelet Rich Plasma and Stem Cell Alopecia Treatment market is split into various segments to provide an in-depth understanding of the different aspects of the Platelet Rich Plasma and Stem Cell Alopecia Treatment market at the granular level. The growth potential, market size, share, and future prospects of each segment and sub-segment is illustrated in the report.

competitive landscape of the industrial workwear market, thereby positioning all the major players according to their geographic presence and recent key developments. The comprehensive industrial workwear market estimates are the result of our in-depth secondary research, primary interviews, and in-house expert panel reviews. These market estimates have been analyzed by taking into account the impact of different political, social, economic, technological, and legal factors along with the current market dynamics affecting the growth of the industrial workwear market. Market share analysis has been included under the competitive landscape to understand the top players contribution to the market. Each company is studied on the basis of basic information, financial highlights, revenue highlights of regional contribution and segment contribution, and product portfolio. Additionally, the company strategy and recent developments if any are also incorporated under each company profile section.

Some of the key players in the industrial workwear market include 3M, VF Corporation, Ansell Ltd., and Honeywell International Ltd., E. I. du Pont de Nemours and Company, Williamson-Dickie Manufacturing Co., Hultafors Group, Lakeland Inc., Aramark, and Fristads Kansas Group. The key players operating in the industrial workwear market adopt numerous strategies to sustain in the market. Product development and acquisition and partnership are some of the main strategies adopted by key players to gain a competitive edge.

The industrial workwear market is segmented as follows:

Industrial Workwear Market

By Product Type

By End-use Industry

By Fit Type

By Distribution Channel

By Geography

RequestTOC For ThisReport @ https://www.transparencymarketresearch.co/sample/sample.php?flag=T&rep_id=55800

Why Opt for TMR?

More here:
Platelet Rich Plasma and Stem Cell Alopecia Treatment Market is Projected to Reach US$XX by the end of 2018 - 2026 - Markets Gazette 24

Does Mayo do anything with Stem cell treatments for copd …

Hi all,One of Mayo Clinic's focus area of Regenerative Medicine is in Lung Regeneration. Learn more here: http://www.mayo.edu/research/centers-programs/center-regenerative-medicine/focus-areas/lung-regeneration

It can be really difficult to tell which stem cell therapies and regenerative medicine practices are effective and which institutions are offering evidence-based proven therapies. In fact, recently the Food and Drug Administration (FDA) released a stern warning against unproven stem cell therapies. The FDA issued these two press statements: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm573427.htm and https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm573431.htm.

To help people learn more about the proven therapies and the promise of developing therapies, Mayo Clinic offers a free telephone consult service. When you call the consult service, they will tell you about the availability of approved stem cell therapy at Mayo Clinic and elsewhere, and for what conditions. They can also tell you about research studies that are actively recruiting participants. Furthermore, you can add your name to a database to be notified when additional studies and information become available. You can learn more about the Consult Service here http://www.mayo.edu/research/centers-programs/center-regenerative-medicine/patient-care/clinical-services/regenerative-medicine-consult-service.Or call 1-844-276-2003 to speak with one of our experts.

@oldman1946, I agree with @kpeace. It's important to do your research to ensure that the promised therapy is evidence-based and not just a money grab.

Jump to this post

View post:
Does Mayo do anything with Stem cell treatments for copd ...